TrialA Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Trial details
- Registry ID
- NCT05288504
- Phase
- Phase 2
AVTX
Avalo Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.NCT05288504 | AVTX | Phase 2 | Completed | 2023-05-11Actual |
| A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaNCT06603077 | AVTX | Phase 2 | Completed | 2026-02-23Actual |
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Trial details
- Registry ID
- NCT06603077
- Phase
- Phase 2
Latest recorded trial changes
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077 · Avalo Therapeutics, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
250 participants (planned)
+ After
253 participants (actual)
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077 · Avalo Therapeutics, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Mar 2026
+ After
23 Feb 2026
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077 · Avalo Therapeutics, Inc.
Planned enrollment increased by 28 participants
− Before
222 participants (planned)
+ After
250 participants (planned)
Primary completion date changed
− Before
Jun 2026
+ After
Mar 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting